FDA Approves Primary Biliary Cirrhosis Treatment
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




FDA Approves Primary Biliary Cirrhosis Treatment

MONTREAL, QC -- December 11, 1997 -- The United States Food and Drug Administration (FDA) has granted manufacturing and marketing clearance to Urso(R) (ursodiol 250 mg tablets) for the treatment of primary biliary cirrhosis (PBC).

PBC is a chronic, progressive cholestatic liver disease of unknown origin. Some 50,000 people in the United States have the disease. At present, patients survive an average of 10 years after diagnosis. Liver transplant is the only current treatment modality for end-stage patients.

Findings indicate that Urso is the only effective and safe drug for the treatment of PBC. It improves the survival rate of patients free of liver transplantation and improves liver biochemistry.

The drug will be marketed in the United States by Axcan Schwarz LLC, a joint venture created in January 1997 by Axcan Pharma Inc. and Schwarz Pharma US.

More information on: Axcan, Urso

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities